Alterity Therapeutics (ATHE) announced that the last patient in the ATH434-201 Phase 2 trial, a randomized, double-blind, placebo-controlled investigation in early-stage multiple system atrophy, MSA,, has completed the study. With the achievement of this milestone, topline results are expected to be reported in late January or early February 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHE:
- Alterity Therapeutics appoints Abby Macnish Niven as secretary
- Alterity Therapeutics announces presentation on bioMUSE study
- Alterity Therapeutics announces new publication on ATH434
- Alterity Therapeutics reports cash balance of A$9.28M as of September 30
- Alterity Therapeutics to Present at Healthcare Summit